BIO-key International, Inc. Reports 18% Revenue Growth in Q3 2024 and Improved Financial Performance
BIO-key International, Inc. Reports 18% Revenue Growth in Q3 2024 and Improved Financial Performance
BIO-key International reported Q3'24 revenue of $2.1M, an 18% increase, with reduced net loss and improved gross profit.
BIO-key International報告2024財年第三季度營業收入爲$2.1 million,增長18%,淨損失減少,毛利提高。
Quiver AI Summary
Quiver AI 概要
BIO-key International, Inc. reported its third quarter financial results for 2024, showing an 18% increase in revenues, reaching $2.1 million, primarily due to higher license revenue from existing customers. The company's gross profit significantly improved to $1.7 million with a gross margin of 78.3%, contrasted with a low margin in the previous year, aided by reduced costs and an absence of hardware reserves previously recorded. Despite a net loss of $0.7 million, the loss was an improvement compared to $1.8 million in Q3 2023. BIO-key also highlighted significant customer orders and partnerships, including a notable upgrade order from a financial services customer, emphasizing its strong market position and potential for future growth. Looking ahead, the company anticipates revenues for the full year 2024 to meet or exceed previous figures while continuing efforts to reduce costs and improve cash flow. An investor call is scheduled for November 15 to discuss the results.
BIO-key International報告了截至2024年第三季度的財務業績,顯示營收增長18%,達到$2.1 million,主要是由於現有客戶授權收入增加。公司的毛利大幅提高至$1.7 million,毛利率爲78.3%,與前一年低毛利相比有顯著改善,得益於成本降低和之前記錄的硬件準備金不再計入。儘管淨損失爲$0.7 million,但與2023年第三季度的$1.8 million相比有所改善。BIO-key還突出了重大客戶訂單和合作夥伴關係,包括來自一家金融服務客戶的顯著升級訂單,強調其在市場上的強勢地位和未來增長潛力。展望未來,該公司預計2024全年營收將達到或超過之前的數字,同時繼續努力降低成本和改善現金流。投資者電話會議定於11月15日討論業績。
Potential Positives
潛在的積極因素
- Q3'24 revenues rose 18% year-over-year to $2.1M, primarily driven by a significant increase in license revenue.
- Gross profit improved to $1.7M with a gross margin of 78.3%, showcasing a substantial shift in profitability compared to the same quarter last year.
- The company successfully reduced operating expenses by $46,000, indicating effective cost management strategies.
- BIO-key secured significant contracts, including a $910k order from a long-time customer and a $500k follow-on order from a defense ministry, highlighting strong demand for its solutions.
- 2024財年第三季度營收同比增長18%,達到$2.1 million,主要受到授權收入大幅增加的推動。
- 毛利提高至$1.7 million,毛利率爲78.3%,較去年同期有實質性盈利能力轉變。
- 公司成功減少營業費用$46,000,表明有效的成本管理策略。
- BIO-key獲得重大合同,包括一份長期客戶的價值$910,000的訂單以及一份來自國防部的後續訂單價值$500,000,凸顯其解決方案的強勁需求。
Potential Negatives
潛在負面影響
- Despite a year-over-year revenue increase, total revenues for the nine months ended September 30, 2024, decreased compared to the same period in 2023, indicating an overall decline in performance.
- The company experienced a loss of a large recurring service agreement and a significant customization customer, which negatively affected service revenues.
- Continued reliance on warrant inducement agreements to raise capital indicates potential financial instability and reliance on unconventional funding methods.
- 儘管從年度收入增長,截至2024年9月30日的九個月總收入與2023年同期相比有所下降,表明績效總體下降。
- 公司經歷了一筆大額經常性服務協議和一個重要定製客戶的流失,對服務收入產生了負面影響。
- 繼續依賴權證誘因協議籌集資本,表明潛在的財務不穩定性和對非傳統籌款方法的依賴。
FAQ
FAQ
What are BIO-key's Q3 2024 revenue results?
bio-key international的2024年第三季度營收結果是什麼?
BIO-key reported Q3 2024 revenues of $2.1M, an 18% increase from $1.8M in Q3 2023, driven by license revenue growth.
bio-key international報告2024年第三季度營收爲210萬美元,比2013年第三季度的180萬美元增長了18%,這得益於許可收入增長。
How did gross profit change in Q3 2024?
2024年第三季度,毛利潤髮生了什麼變化?
Gross profit improved to $1.7M in Q3 2024, reflecting a 78.3% gross margin, up from $0.3M in the prior year.
毛利潤在2024年第三季度提高至170萬美元,毛利率爲78.3%,高於前一年的30萬美元。
What were the key highlights for BIO-key after Q3 2024?
2024年第三季度後的BIO-key主要亮點是什麼?
Key highlights include a $910k order for financial services, a $500k defense contract, and 10,000 additional users in British Columbia.
主要亮點包括金融服務的91萬美元訂單,50萬美元的國防合同,以及在不列顛哥倫比亞省增加了1萬名用戶。
When will BIO-key host its investor call?
BIO-key將在何時舉行投資者電話會議?
BIO-key will host an investor call on November 15, 2024, at 10:00 AM ET to discuss these results.
BIO-key將於2024年11月15日上午10:00(東部時間)舉行投資者電話會議,討論這些結果。
What is BIO-key's outlook for the full year 2024?
BIO-key對2024年全年的展望如何?
BIO-key expects full year 2024 revenues to meet or exceed the $7.75M achieved in 2023, focusing on high-margin revenue streams.
BIO-key預計2024年全年的營業收入將達到或超過2023年的775萬美元,專注於高利潤的營收領域。
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
免責聲明:這是由GlobeNewswire分發的新聞稿的人工智能生成摘要。用於總結這份稿件的模型可能會出錯。請在這裏查看完整發布。
$BKYI Hedge Fund Activity
BKYI對沖基金活動
We have seen 4 institutional investors add shares of $BKYI stock to their portfolio, and 5 decrease their positions in their most recent quarter.
我們看到有4家機構投資者在最近一個季度向其投資組合中增加了$BKYI股票的數量,而有5家減少了他們的持股。
Here are some of the largest recent moves:
以下是一些最近最大的交易動態:
- ARMISTICE CAPITAL, LLC added 250,000 shares (+inf%) to their portfolio in Q3 2024
- GEODE CAPITAL MANAGEMENT, LLC removed 12,108 shares (-100.0%) from their portfolio in Q3 2024
- UBS GROUP AG added 2,005 shares (+454.6%) to their portfolio in Q2 2024
- TOWER RESEARCH CAPITAL LLC (TRC) removed 714 shares (-12.1%) from their portfolio in Q3 2024
- GROUP ONE TRADING, L.P. removed 334 shares (-100.0%) from their portfolio in Q2 2024
- WELLS FARGO & COMPANY/MN added 39 shares (+1300.0%) to their portfolio in Q3 2024
- ABICH FINANCIAL WEALTH MANAGEMENT LLC removed 37 shares (-100.0%) from their portfolio in Q3 2024
- 愛文思控股公司在2024年第三季度將25萬股(+inf%)加入其投資組合
- GEODE CAPITAL MANAGEMENt, LLC在2024年第三季度從其投資組合中減少了12,108股(-100.0%)
- 瑞銀增加了2,005股(+454.6%)至其2024年第二季度投資組合
- 特斯拉-儀表研究資本有限責任公司(TRC)在2024年第三季度將714股(-12.1%)從其投資組合中刪除
- Group One Trading,L.P.在2024年第二季度從其投資組合中減少了334股(-100.0%)
- 富國銀行公司在2024年第三季度向其投資組合增加了39股(+1300.0%)
- ABICH金融财富管理有限公司在2024年第三季度從其投資組合中剔除37股(-100.0%)
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
要追蹤對沖基金的股票組合,請查看Quiver Quantitative的機構持股儀表板。
Full Release
全面發佈
HOLMDEL, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) --
BIO-key
International, Inc.
(Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, announced results for its third quarter ended September 30, 2024 (Q3'24). BIO-key's 2023 Q3 and nine month results were restated and filed with the Company's
2023 Form 10-K
and are reflected in this release. BIO-key will host an investor call tomorrow, Friday, November 15th at 10:00am ET (details below).
2024年11月14日,新澤西州霍爾姆德爾(HOLMDEL)(GLOBE NEWSWIRE)
生物密鑰
國際公司,股份有限公司
(納斯達克:BKYI),一家創新的勞工和客戶身份和訪問管理(IAM)解決方案的提供商,涵蓋了無密碼、無手機和無令牌的身份綁定生物識別(IBB)認證,宣佈截至2024年9月30日的第三季度(Q3'24)的業績。生物密鑰的2023年第三季度和前九個月的業績已經重新規定並提交給該公司
2023年10-K表格
這些內容已反映在此版本中。 BIO-key將於明天主持投資者電話,即11月15日星期五上午10:00 Et(詳細信息如下)。
Financial Highlights
財務亮點
-
Q3'24 revenues rose 18% to $2.1M from $1.8M in Q3'23, principally due to a $0.5M increase in license revenue related to expanded software deployments by long-term customers.
-
Gross profit improved to $1.7M (78.3% gross margin) in Q3'24 vs. $0.3M (18.7% gross margin) in Q3'23, due to an increase in high-margin license revenue, lower costs to support deployments, and a $1M hardware reserve taken in the prior-year period.
-
BIO-key trimmed Q3'24 operating expenses by $46,000 versus Q3'23, reflecting proactive reductions in administration, sales personnel costs and marketing show expenses, offset by higher professional services expenses principally related to financing activities.
-
BIO-key reported a Q3'24 net loss of $0.7M compared to a Q3'23 net loss of $1.8M, due primarily to an increase in high-margin license revenue, level operating expenses, and the prior-year hardware reserve.
-
Cash used in operating activities was $2.4M through the first nine months of 2024 vs. $2.3M in the prior-year period. The current-year period reflects BIO-key's net loss through the first nine months and positive adjustments for non-cash expenses of approximately $667,000.
-
2024年第三季度營收同比增長18%,從第三季度23的180萬美元增至210萬美元,主要是由於長期客戶擴大軟件部署導致的許可收入增加50萬美元。
-
2024財年第三季度毛利潤提升至170萬美元(78.3%毛利率),相比第23財年第三季度的30萬美元(18.7%毛利率),主要是由於高毛利的許可收入增加,支持部署成本降低,以及在前一年度期間提取的100萬美元硬件準備金。
-
BIO-key將第三財季營業費用削減46,000美元,與第三財季23相比,主要體現了管理、銷售人員成本和市場費用的積極降低,但由於專業服務費用增加,主要與融資活動相關。
-
與第三財季23相比,BIO-key第三財季24淨虧損爲70萬美元,而第23財季淨虧損爲180萬美元,主要原因是高毛利許可收入增加,營業費用保持穩定,以及前一年度硬件準備金。
-
2024年前九個月營運活動中的現金使用額爲240萬美元,而前一年同期爲230萬美元。本年度前九個月反映了BIO-key的淨虧損和約667,000美元的非現金費用的積極調整。
Recent Highlights
最近的亮點
-
Following the close of Q3'24,
BIO-key Secured a $910k Order
to Upgrade a Long-time Financial Services Customer to its Enhanced Biometric Customer Identification Technology
-
A
Leading International Defense Ministry Awarded BIO-key $500k in Follow-On Order
s
for Biometric User Authentication
-
British Columbia Added 10,000 Users to its BIO-key Biometric Solution Deployment
for Sign-on and Physical Access Control
-
BIO-key's PortalGuard Identity and Access Management Solution and Identity-Bound Biometrics Became
Available on the Amazon Web Services (AWS) Marketplace
-
Williamsburg, VA
advanced its Zero Trust initiative with BIO-key's Identity-Bound Biometrics.
-
BIO-key Raised $1.9M in Gross Proceeds via
Warrant Inducement
-
在2024年第三季度結束後,
bio-key international贏得了91萬美元的訂單
將長期金融服務客戶升級到其增強的生物識別客戶身份驗證技術
-
A
領先國際國防部向BIO-key授予50萬美元的跟單訂單
s
用於生物識別用戶身份驗證
-
不列顛哥倫比亞省在其BIO-key生物特徵解決方案部署中增加了10,000個用戶
用於登錄和物理訪問控制
-
BIO-key的PortalGuard身份和訪問管理解決方案與身份綁定生物識別技術變得
可在亞馬遜網絡服務(AWS)市場上獲取
-
威廉斯堡,弗吉尼亞州
通過BIO-key的身份綁定生物識別技術,加快了其零信任計劃。
-
BIO-key通過募集190萬美元的毛收入金額
認股權誘因
Commentary
BIO-key CEO, Mike DePasquale commented, "We had a very productive third quarter, with revenue increasing 18% year-over-year and $1M compared to Q2'24, supported by license fee revenue which rose to $1.4M in Q3'24 from $1.0M in Q3'23. Our Q3'24 revenues reflected strength in orders from existing customers who are expanding their deployment of BIO-key solutions. This momentum continued into Q4 with an exciting order from a long-time foreign financial services customer to utilize our biometric identification technology for customer identification within their branches.
評論
BIO-key CEO, Mike DePasquale commented, "We had a very productive third quarter, with revenue increasing 18% year-over-year and $100萬 compared to Q2'24, supported by license fee revenue which rose to $140萬 in Q3'24 from $100萬 in Q3'23. Our Q3'24 revenues reflected strength in orders from existing customers who are expanding their deployment of BIO-key solutions. This momentum continued into Q4 with an exciting order from a long-time foreign financial services customer to utilize our biometric identification technology for customer identification within their branches.
"This firm has already enrolled the fingerprint biometrics of over 25M of its customers using BIO-key technology as part of its know your customer (KYC) process. They are now upgrading to BIO-key's "fingerprint only" identification solution which will enable them to identify each of their customers with just a fingerprint scan, eliminating the need for a bank card, account or ID number. This highly secure and efficient identification approach is expected to save an estimated thirty seconds per client encounter, benefiting both customers and bank personnel.
"This firm has already enrolled the fingerprint biometrics of over 2500萬 of its customers using BIO-key technology as part of its know your customer (KYC) process. They are now upgrading to BIO-key's "fingerprint only" identification solution which will enable them to identify each of their customers with just a fingerprint scan, eliminating the need for a bank card, account or ID number. This highly secure and efficient identification approach is expected to save an estimated thirty seconds per client encounter, benefiting both customers and bank personnel.
"We believe this is one of the world's largest deployments of one-to-many biometric technology in a private commercial or enterprise setting, as compared to one-to-one matching of a fingerprint scan with a biometric associated with an account, ID number or card. Working with the client and our partner at AWS, we intend to publish a more detailed whitepaper on this deployment to fully explain the unique benefits our advanced biometric identity solutions can provide to other enterprises. We are of course very excited about this large-scale adoption of our technology and look to leverage the value and benefits of use in this example for our direct and Channel Alliance Partner (CAP) sales programs.
"We believe this is one of the world's largest deployments of one-to-many biometric technology in a private commercial or enterprise setting, as compared to one-to-one matching of a fingerprint scan with a biometric associated with an account, ID number or card. Working with the client and our partner at AWS, we intend to publish a more detailed whitepaper on this deployment to fully explain the unique benefits our advanced biometric identity solutions can provide to other enterprises. We are of course very excited about this large-scale adoption of our technology and look to leverage the value and benefits of use in this example for our direct and Channel Alliance Partner (CAP) sales programs.
"Given the nature of our size and the timing and impact of larger customer orders, we do expect our performance to vary on a quarter-to-quarter basis as we build a growing base of high-margin, annually recurring revenue streams from software licenses and services. We expect full year 2024 revenues to meet or exceed the $7.75M achieved in 2023, and we continue to pursue opportunities to lower our overhead and variable costs, as we progress the business toward positive operating cash flow and profitability in the coming quarters. Additionally, we continue to seek potential strategic opportunities that can leverage our core strengths and business platform to create value for our shareholders.
"Given the nature of our size and the timing and impact of larger customer orders, we do expect our performance to vary on a quarter-to-quarter basis as we build a growing base of high-margin, annually recurring revenue streams from software licenses and services. We expect full year 2024 revenues to meet or exceed the $775萬 achieved in 2023, and we continue to pursue opportunities to lower our overhead and variable costs, as we progress the business toward positive operating cash flow and profitability in the coming quarters. Additionally, we continue to seek potential strategic opportunities that can leverage our core strengths and business platform to create value for our shareholders.
"From a financial perspective, we were able to raise $1.9M during the third quarter through a warrant inducement agreement, pursuant to which an existing institutional investor exercised warrants to purchase 1,030,556 BIO-key shares at $1.85 per share. Reflecting these proceeds, our cash position improved to $1.8M at close of Q3'24 vs. $0.5M at year end 2023."
從財務角度來看,我們通過認股權誘因協議在第三季度成功籌集了190萬美元,根據該協議,一位現有機構投資者行使認股權,以每股1.85美元的價格購買1030556股BIO-key股票。反映這些收入,我們的現金狀況在2024年第3季度結束時改善至180萬美元,而在2023年年底爲50萬美元。
Financial Results
BIO-key's Q3'24 revenues increased 18% to $2.1M from $1.8M in Q3'23. License revenue increased $491,000 or 52% to $1.4M and hardware sales increased 56% to $436,000, as several long-term customers expanded their license deployments and purchased additional biometric readers. Declines in recurring and non-recurring service revenues of $320,522 stemmed from the loss of one large recurring service agreement and one large customization customer from the prior-year period. For the nine months ended September 30, 2024, revenues were $5.5M compared to $5.9M in the comparable 2023 period, as increased license fees and hardware revenue was offset by lower service revenues.
財務結果
BIO-key的2024年第3季度營收同比增長18%,達到210萬美元,較2023年第3季度的180萬美元有所增加。許可證營收增加了491,000美元,增長了52%,達到140萬美元,硬件銷售增長了56%,達到436,000美元,因爲幾位長期客戶擴大了許可部署,併購買了更多生物識別讀卡器。320,522美元的經常性和非經常性服務收入下降是由於失去了一個大型經常性服務協議和一個大型客戶定製客戶所致。截至2024年9月30日的九個月內,收入爲550萬美元,而在可比的2023年同期爲590萬美元,增加的許可費和硬件收入被較低的服務收入抵消。
Q3'24 Gross profit was $1.7M (78.3% gross margin) versus $0.3M (18.7% gross margin) in Q3'23, primarily reflecting the impact of a $1M hardware reserve in Q3'23, a higher proportion of high margin license fee revenue in Q3'24, and lower costs to support deployments, including license fees for third-party software included in BIO-key's Swivel Secure offerings.
2024年第3季度的毛利爲170萬美元(毛利率78.3%),而2023年第3季度爲30萬美元(毛利率18.7%),主要反映了2023年第3季度100萬美元的硬件準備金的影響,2024年第3季度高毛利許可費收入比例更高,以及降低支持部署的成本,包括BIO-key Swivel Secure產品中包含的第三方軟件的許可費降低。
BIO-key trimmed operating expenses by $46,000 in Q3'24 versus Q3'23, reflecting reductions in administration expenses, including lower headquarters expense, sales personnel costs, and marketing show expenses, partially offset by an increase in professional services, principally related to the Company's financing activities. Also offsetting lower SG&A costs was a $122,000 increase in research, development and engineering expense due to increased personnel costs to support new product development.
與2023年第3季度相比,BIO-key在2024年第3季度將營業費用削減了46,000美元,反映出管理費用的降低,包括較低的總部費用、銷售人員成本以及市場展示費用,部分抵消了專業服務費用的增加,主要與公司的融資活動有關。抵消銷售和管理費用下降的還有研發費用增加122,000美元,主要是由於增加的人員成本支持新產品開發。
Reflecting higher revenue and gross profit and flat operating expenses, BIO-key's net loss improved to $0.7M, or $0.39 per share, in Q3'24, from a net loss of $1.8M, or $3.22 per share, in Q3'23. Likewise, BIO-key reduced its net loss for the first nine months of 2024 to $2.9M, or $1.69 per share, compared to a net loss of $6.1M, or $10.79 per share, in the first nine months of 2023. Q3'23 results included the hardware reserve of $1.0M and the first nine months of 2023 included a hardware reserve of $2.5M.
反映出收入和毛利的增加以及營業費用持平,BIO-key在2024年第3季度的淨虧損從2023年第3季度的180萬美元,或每股3.22美元,改善至70萬美元,或每股0.39美元。同樣,BIO-key將2024年頭9個月的淨虧損降至290萬美元,或每股1.69美元,而在2023年頭9個月是610萬美元,或每股10.79美元。2023年第3季度的結果包括100萬美元的硬件準備金,而2023年頭9個月包括250萬美元的硬件準備金。
Balance Sheet
At September 30, 2024, BIO-key had current assets of approximately $4.6M, including $1.8M of cash and cash equivalents, $2.0M of net accounts receivable and due from factor, and $387,000 of inventory. This compares to current assets of $2.6M at December 31, 2023, including approximately $511,000 of cash equivalents, $1.3M of net accounts receivable and due from factor, and $446,000 of inventory.
資產負債表:
截至2024年9月30日,BIO-key的流動資產約爲460萬美元,包括180萬美元的現金及現金等價物,200萬美元的淨應收賬款和應收因素,及387,000美元的存貨。與2023年12月31日的流動資產260萬美元相比,後者包括約511,000美元的現金等價物,130萬美元的淨應收賬款和應收因素以及446,000美元的存貨。
Conference Call Details | ||
Date / Time: |
Friday, November 15th at 10 a.m. ET |
|
Call Dial In #: |
1-877-418-5460 U.S. or 1-412-717-9594 Int'l |
|
Live Webcast / Replay: |
Webcast & Replay Link – Available for 3 months. |
|
Audio Replay: |
1-877-344-7529 U.S. or 1-412-317-0088 Int'l; code 7307131 |
電話會議詳情 | ||
日期/時間: |
週五,11月15日 在 美東時間上午10點 |
|
看漲撥號號碼: |
美國電話:1-877-418-5460,國際電話:1-412-717-9594 |
|
直播網絡廣播 / 重播: |
網絡廣播及重播鏈接 – 提供3個月。 |
|
音頻重播: |
美國:1-877-344-7529;國際:1-412-317-0088;密碼7307131 |
About BIO-key International, Inc. (
)
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.
關於bio-key international公司(
)
BIO-key正在通過生物識別中心的多因素身份和訪問管理(iam)軟件革新身份驗證和網絡安全,爲超過四千萬用戶提供安全訪問。BIO-key允許客戶根據不同的使用案例選擇合適的身份驗證因素,包括無手機、無需令牌和無密碼的生物識別選項。其託管或本地的PortalGuard iam解決方案提供經濟高效、易於部署、方便和安全的計算機、信息、應用程序以及高價值交易的訪問。
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of Swivel Secure into our business; fluctuations in foreign currency exchange rates; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence the restatement of our financial statements, including any consequences of non-compliance with Securities and Exchange Commission and Nasdaq periodic reporting requirements; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future; if we fail to increase our stockholders' equity to at least $2.5 million, our common stock will be delisted from the Nasdaq Capital Market which could negatively impact the trading price of our common stock and impair our ability to raise capital, any disruption to our business that may occur on a longer-term basis should we be unable to remediate during fiscal year 2024 certain material weaknesses in our internal controls over financial reporting, and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
BIO-key安全港聲明
本新聞稿中包含的所有聲明,除了歷史事實陳述之外,均屬於1995年《私人證券訴訟改革法案》("法案")定義的"前瞻性陳述"。"估計," "計劃," "打算," "期望," "預計," "相信" 等類似表達旨在識別前瞻性聲明。此類前瞻性聲明是基於管理層的信念,並根據管理層根據法案"安全港"條款所作的假設和當前可獲得的信息。這些聲明並非未來績效或事件的保證,可能受到風險和不確定性的影響,這些風險和不確定性可能導致實際結果與此類前瞻性聲明所包含的結果有實質差異,或受到暗示。這些風險和不確定性包括但不限於我們的虧損歷史和有限營收;我們籌集額外資本以滿足營運資本需求的能力;我們作爲持續存續實體的能力;我們保護知識產權的能力;商業條件的變化;我們銷售策略和產品開發計劃的變化;市場的變化;我們執行管理團隊的繼續服務;安全漏洞;生物識別技術行業的競爭;生物識別產品普遍受市場認可和我們開發中產品的市場認可度;我們能否將銷售機會轉化爲客戶合同;我們能否拓展至亞洲、非洲和其他外國市場;我們能否將Swivel Secure的運營和人員整合到我們的業務;外匯匯率波動;產品開發的延遲;商業、聲譽和監管風險可能會導致我們財務報表重新編制,包括不符合證券交易委員會和納斯達克定期報告要求的任何後果;如果我們未能將我們的股東權益增加至至少250萬美元,我們的普通股將從納斯達克資本市場除牌,可能會對我們的普通股交易價格造成負面影響,並損害我們籌集資本的能力,若我們無法在2024財年期間修正我們財務報告內部控制某些重大缺陷,則在較長期內可能會對我們業務造成任何干擾。未納入任何上述陳述的假設,以及其他因素列在我們於2023年12月31日結束的年度10-K報告"風險因素"標題下,以及我們向證券交易委員會提交的其他文件中。讀者被告誡不要過分依賴這些前瞻性陳述,這些陳述僅在製作日期有效。除法律要求外,我們不承諾對這些前瞻性陳述進行任何修訂,無論是因新信息、未來事件,還是其他原因。
Engage with BIO-key | ||
Facebook – Corporate: |
|
|
LinkedIn – Corporate: |
|
|
X – Corporate: |
@BIOkeyIntl |
|
X – Investors: |
@BIO_keyIR |
|
StockTwits: |
BIO_keyIR |
與bio-key互動 | ||
Facebook公司頁面: |
|
|
Linkedin公司頁面: |
|
|
X – 公司: |
@bio-key international |
|
X – 投資者: |
@BIO_keyIR |
|
StockTwits: |
BIO_keyIR |
Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com
or 212-924-9800
投資者聯繫方式
William Jones,David Collins
Catalyst IR
BKYI@catalyst-ir.com
或者212-924-9800
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) | ||||||||||||||||
Three Months Ended |
Nine Months Ended |
|||||||||||||||
September 30, |
September 30, |
|||||||||||||||
2024 |
2023 |
2024 |
2023 |
|||||||||||||
Revenues |
||||||||||||||||
Services |
$ |
267,371 |
$ |
587,893 |
$ |
764,062 |
$ |
1,740,880 |
||||||||
License fees |
1,441,011 |
950,015 |
4,165,669 |
3,764,342 |
||||||||||||
Hardware |
436,422 |
279,200 |
537,562 |
424,582 |
||||||||||||
Total revenues |
2,144,804 |
1,817,108 |
5,467,293 |
5,929,804 |
||||||||||||
Costs and other expenses |
||||||||||||||||
Cost of services |
110,723 |
125,039 |
322,957 |
639,996 |
||||||||||||
Cost of license fees |
146,732 |
253,891 |
443,384 |
1,022,919 |
||||||||||||
Cost of hardware |
207,655 |
97,674 |
260,684 |
240,074 |
||||||||||||
Cost of hardware - reserve |
- |
1,000,000 |
- |
2,500,000 |
||||||||||||
Total costs and other expenses |
465,110 |
1,476,604 |
1,027,025 |
4,402,989 |
||||||||||||
Gross profit |
1,679,694 |
340,504 |
4,440,268 |
1,526,815 |
||||||||||||
Operating Expenses |
||||||||||||||||
Selling, general and administrative |
1,607,925 |
1,776,305 |
5,332,764 |
5,851,201 |
||||||||||||
Research, development and engineering |
652,174 |
529,757 |
1,850,929 |
1,778,097 |
||||||||||||
Total Operating Expenses |
2,260,099 |
2,306,062 |
7,183,693 |
7,629,298 |
||||||||||||
Operating loss |
(580,405 ) |
(1,965,558 ) |
(2,743,425 ) |
(6,102,483 ) |
||||||||||||
Other income (expense) |
||||||||||||||||
Interest income |
2 |
5,917 |
53 |
5,944 |
||||||||||||
Loss on foreign currency transactions |
- |
- |
- |
(15,000 ) |
||||||||||||
Loan fee amortization |
(60,000 ) |
- |
(64,000 ) |
- |
||||||||||||
Change in fair value of convertible note |
- |
167,283 |
- |
264,706 |
||||||||||||
Interest expense |
(98,556 ) |
(45,655 ) |
(108,823 ) |
(159,380 ) |
||||||||||||
Total other income (expense), net |
(158,554 ) |
127,545 |
(172,770 ) |
96,270 |
||||||||||||
Loss before provision for income tax |
(738,959 ) |
(1,838,013 ) |
(2,916,195 ) |
(6,006,213 ) |
||||||||||||
Provision for (income tax) tax benefit |
- |
189 |
- |
(142,811 ) |
||||||||||||
Net loss |
$ |
(738,959 ) |
$ |
(1,837,824 ) |
$ |
(2,916,195 ) |
$ |
(6,149,024 ) |
||||||||
Comprehensive loss: |
||||||||||||||||
Net loss |
$ |
(738,959 ) |
$ |
(1,837,824 ) |
$ |
(2,916,195 ) |
$ |
(6,149,024 ) |
||||||||
Other comprehensive income (loss) – Foreign currency translation adjustment |
89,933 |
35,364 |
51,878 |
127,394 |
||||||||||||
Comprehensive loss |
$ |
(649,026 ) |
$ |
(1,802,460 ) |
$ |
(2,864,317 ) |
$ |
(6,021,630 ) |
||||||||
Basic and Diluted Loss per Common Share |
$ |
(0.39 ) |
$ |
(3.22 ) |
$ |
(1.69 ) |
$ |
(10.79 ) |
||||||||
Weighted Average Common Shares Outstanding: |
|
|
|
|
||||||||||||
Basic and diluted |
1,889,694 |
570,753 |
1,726,716 |
569,882 |
||||||||||||
All BIO-key shares issued and outstanding for all periods reflect BIO-key's 1-for-18 reverse stock split, which was effective December 21, 2023. |
bio-key international公司及其子公司 綜合損失及綜合損益簡明綜合表 (未經審計) | ||||||||||||||||
截至三個月 |
截至九個月 |
|||||||||||||||
9月30日, |
9月30日, |
|||||||||||||||
2024 |
2023 |
2024 |
2023 |
|||||||||||||
收入 |
||||||||||||||||
服務 |
$ |
267,371 |
$ |
587,893 |
$ |
764,062 |
$ |
1,740,880 |
||||||||
許可證費用 |
1,441,011 |
950,015 |
4,165,669 |
3,764,342 |
||||||||||||
硬件 |
436,422 |
279,200 |
537,562 |
424,582 |
||||||||||||
總收入 |
2,144,804 |
1,817,108 |
5,467,293 |
5,929,804 |
||||||||||||
成本及其他費用 |
||||||||||||||||
服務成本 |
110,723 |
125,039 |
322,957 |
639,996 |
||||||||||||
許可費用 |
146,732 |
253,891 |
443,384 |
1,022,919 |
||||||||||||
硬件成本 |
207,655 |
97,674 |
260,684 |
240,074 |
||||||||||||
硬件成本 - 儲備 |
- |
1,000,000 |
- |
2,500,000 |
||||||||||||
總成本和其他費用 |
465,110 |
1,476,604 |
1,027,025 |
4,402,989 |
||||||||||||
毛利潤 |
1,679,694 |
340,504 |
4,440,268 |
1,526,815 |
||||||||||||
運營費用 |
||||||||||||||||
銷售、一般及行政費用 |
1,607,925 |
1,776,305 |
5,332,764 |
5,851,201 |
||||||||||||
研究、開發和工程 |
652,174 |
529,757 |
1,850,929 |
1,778,097 |
||||||||||||
總營業費用 |
2,260,099 |
2,306,062 |
7,183,693 |
7,629,298 |
||||||||||||
營業損失 |
(580,405 ) |
(1,965,558 ) |
(2,743,425 ) |
(6,102,483 ) |
||||||||||||
其他收入(費用) |
||||||||||||||||
利息收入 |
2 |
5,917 |
53 |
5,944 |
||||||||||||
外匯交易損失 |
- |
- |
- |
投資活動產生的現金流量淨額:(15,000美元) ) |
||||||||||||
貸款手續費的攤銷。 |
(60,000 ) |
- |
(64,000 ) |
- |
||||||||||||
可轉換債券公允價值變動 |
- |
167,283 |
- |
264,706 |
||||||||||||
利息支出 |
(98,556 ) |
(45,655 ) |
(108,823 ) |
(159,380 ) |
||||||||||||
其他總收益(費用),淨額 |
(158,554 ) |
127,545 |
(172,770 ) |
96,270 |
||||||||||||
計提所得稅前虧損 |
(738,959 ) |
(1,838,013 ) |
(2,916,195 ) |
(6,006,213 ) |
||||||||||||
所得稅(稅收利益)撥備 |
- |
$ |
- |
(142,811 ) |
||||||||||||
淨虧損 |
$ |
(738,959 ) |
$ |
(1,837,824 ) |
$ |
(2,916,195 ) |
$ |
(6,149,024 ) |
||||||||
綜合虧損: |
||||||||||||||||
淨虧損 |
$ |
(738,959 ) |
$ |
(1,837,824 ) |
$ |
(2,916,195 ) |
$ |
(6,149,024 ) |
||||||||
其他綜合收益(損失)– 外幣翻譯調整 |
89,933 |
35,364 |
51,878 |
127,394 |
||||||||||||
全面損失 |
$ |
(649,026 ) |
$ |
(1,802,460 ) |
$ |
(2,864,317 ) |
$ |
(6,021,630 ) |
||||||||
每股普通股基本和攤薄虧損 |
$ |
(0.39 ) |
$ |
(3.22 ) |
$ |
(1.69 ) |
$ |
(10.79 ) |
||||||||
加權平均股數: |
|
|
|
|
||||||||||||
基本和攤薄 |
1,889,694 |
570,753 |
1,726,716 |
569,882 |
||||||||||||
所有bio-key發行和未流通股份在所有期間反映出bio-key的1比18的股票合併,該合併於2023年12月21日生效。 |
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
September 30, |
December 31, |
|||||||
2024 |
2023 |
|||||||
(Unaudited) |
|
|||||||
ASSETS |
|
|
||||||
Cash and cash equivalents |
$ |
1,801,137 |
$ |
511,400 |
||||
Accounts receivable, net |
1,930,258 |
1,201,526 |
||||||
Due from factor |
49,018 |
99,320 |
||||||
Inventory |
386,944 |
445,740 |
||||||
Prepaid expenses and other |
382,866 |
364,171 |
||||||
Total current assets |
4,550,223 |
2,622,157 |
||||||
Equipment and leasehold improvements, net |
162,551 |
220,177 |
||||||
Capitalized contract costs, net |
430,596 |
229,806 |
||||||
Deposits and other assets |
7,975 |
- |
||||||
Operating lease right-of-use assets |
73,637 |
36,905 |
||||||
Intangible assets, net |
1,174,721 |
1,407,990 |
||||||
Total non-current assets |
1,849,480 |
1,894,878 |
||||||
TOTAL ASSETS |
$ |
6,399,703 |
$ |
4,517,035 |
||||
LIABILITIES |
|
|
||||||
Accounts payable |
$ |
1,564,654 |
$ |
1,316,014 |
||||
Accrued liabilities |
1,254,415 |
1,305,848 |
||||||
Note payable |
2,164,693 |
- |
||||||
Government loan – BBVA Bank, current portion |
141,854 |
138,730 |
||||||
Deferred revenue, current |
719,846 |
414,968 |
||||||
Operating lease liabilities, current portion |
24,545 |
37,829 |
||||||
Total current liabilities |
5,870,007 |
3,213,389 |
||||||
Deferred revenue, long term |
240,664 |
28,296 |
||||||
Deferred tax liability |
22,998 |
22,998 |
||||||
Government loan – BBVA Bank – net of current portion |
83,901 |
188,787 |
||||||
Operating lease liabilities, net of current portion |
49,091 |
- |
||||||
Total non-current liabilities |
396,654 |
240,081 |
||||||
TOTAL LIABILITIES |
6,266,661 |
3,453,470 |
||||||
Commitments and Contingencies |
||||||||
STOCKHOLDERS' EQUITY |
|
|
||||||
Common stock — authorized, 170,000,000 shares; issued and outstanding; 3,109,288 and 1,032,777 of $.0001 par value at September 30, 2024 and December 31, 2023, respectively |
311 |
103 |
||||||
Additional paid-in capital |
127,981,436 |
126,047,851 |
||||||
Accumulated other comprehensive loss |
74,699 |
22,821 |
||||||
Accumulated deficit |
(127,923,404 ) |
(125,007,210 ) |
||||||
TOTAL STOCKHOLDERS' EQUITY |
133,042 |
1,063,565 |
||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ |
6,399,703 |
$ |
4,517,035 |
||||
All BIO-key shares issued and outstanding for all periods reflect BIO-key's 1-for-18 reverse stock split, which was effective December 21, 2023. |
bio-key international公司及其子公司 簡明合併資產負債表 | ||||||||
9月30日, |
2023年12月31日, |
|||||||
2024 |
2023 |
|||||||
(未經審計) |
|
|||||||
資產 |
|
|
||||||
現金及現金等價物 |
$ |
1,801,137 |
$ |
511,400 |
||||
應收賬款,淨額 |
1,930,258 |
1,201,526 |
||||||
來自保理商的應收款 |
49,018 |
99,320 |
||||||
存貨 |
386,944 |
445,740 |
||||||
預付費用及其他 |
382,866 |
364,171 |
||||||
總流動資產 |
4,550,223 |
2,622,157 |
||||||
|
162,551 |
220,177 |
||||||
資本化合同成本,淨額 |
430,596 |
229,806 |
||||||
存款和其他資產 |
7,975 |
- |
||||||
經營租賃使用權資產 |
73,637 |
36,905 |
||||||
無形資產-淨額 |
1,174,721 |
1,407,990 |
||||||
總非流動資產 |
1,849,480 |
1,894,878 |
||||||
資產總計 |
$ |
6,399,703 |
$ |
4,517,035 |
||||
負債 |
|
|
||||||
應付賬款 |
$ |
1,564,654 |
$ |
1,316,014 |
||||
應計負債 |
1,254,415 |
1,305,848 |
||||||
應付票據 |
2,164,693 |
- |
||||||
政府貸款 – BBVA銀行,當前部分 |
141,854 |
138,730 |
||||||
遞延收入,流動 |
719,846 |
414,968 |
||||||
經營租賃負債,當前部分 |
24,545 |
37,829 |
||||||
總流動負債 |
5,870,007 |
3,213,389 |
||||||
遞延收入,長期 |
240,664 |
28,296 |
||||||
遞延所得稅負債 |
22,998 |
22,998 |
||||||
政府貸款 – BBVA銀行 – 淨當前部分 |
83,901 |
188,787 |
||||||
經營租賃負債,淨值超過流動資產 |
49,091 |
- |
||||||
總非流動負債 |
396,654 |
240,081 |
||||||
負債合計 |
6,266,661 |
3,453,470 |
||||||
承諾和事後約定 |
||||||||
股東權益 |
|
|
||||||
普通股——授權170,000,000股;已發行並流通;截至2024年9月30日和2023年12月31日,各爲3,109,288股和1,032,777股,面值爲0.0001美元。 |
311 |
103 |
||||||
追加實收資本 |
127,981,436 |
126,047,851 |
||||||
累計其他綜合損失 |
74,699 |
22,821 |
||||||
累積赤字 |
(127,923,404 ) |
(125,007,210 ) |
||||||
股東權益合計 |
133,042 |
1,063,565 |
||||||
負債合計及股東權益總計 |
$ |
6,399,703 |
$ |
4,517,035 |
||||
所有bio-key發行和未流通股份在所有期間反映出bio-key的1比18的股票合併,該合併於2023年12月21日生效。 |
BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | ||||||||
Nine Months Ended September 30, |
||||||||
2024 |
2023 |
|||||||
CASH FLOW FROM OPERATING ACTIVITIES: |
|
|
||||||
Net loss |
$ |
(2,916,195 ) |
$ |
(6,149,024 ) |
||||
Adjustments to reconcile net loss to net cash used for operating activities: |
|
|
||||||
Depreciation |
69,115 |
38,213 |
||||||
Amortization of intangible assets |
233,269 |
217,978 |
||||||
Change in fair value of convertible note |
- |
(264,706 ) |
||||||
Amortization of capitalized contract costs |
128,953 |
126,057 |
||||||
Amortization of Note Payable |
64,000 |
- |
||||||
Reserve for inventory |
(98,875 ) |
2,500,000 |
||||||
Operating leases right-of-use assets |
(58,950 ) |
146,890 |
||||||
Share and warrant-based compensation for employees and consultants |
162,614 |
163,584 |
||||||
Stock based directors' fees |
9,003 |
39,006 |
||||||
Deferred income tax benefit |
- |
(20,000 ) |
||||||
Bad debts |
- |
550,000 |
||||||
Change in assets and liabilities: |
|
|
||||||
Accounts receivable |
(398,753 ) |
(434,989 ) |
||||||
Due from factor |
50,302 |
(13,072 ) |
||||||
Capitalized contract costs |
(329,743 ) |
(107,336 ) |
||||||
Deposits |
(7,975 ) |
- |
||||||
Inventory |
58,796 |
145,156 |
||||||
Prepaid expenses and other |
(18,695 ) |
(51,831 ) |
||||||
Accounts payable |
248,640 |
488,417 |
||||||
Accrued liabilities |
(51,433 ) |
327,131 |
||||||
Income taxes payable |
- |
62,811 |
||||||
Deferred revenue |
517,246 |
128,253 |
||||||
Operating lease liabilities |
(60,827 ) |
(154,460 ) |
||||||
Net cash used in operating activities |
(2,399,508 ) |
(2,261,922 ) |
||||||
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
||||||
Capital expenditures |
(23,047 ) |
- |
||||||
Net cash used in investing activities |
(23,047 ) |
- |
||||||
CASH FLOW FROM FINANCING ACTIVITIES: |
|
|
||||||
Proceeds from Note Payable |
2,000,000 |
- |
||||||
Offering costs |
(147,862 ) |
(25,434 ) |
||||||
Proceeds for exercise of warrants |
1,908,099 |
- |
||||||
Receipt of cash from Employee stock purchase plan |
1,939 |
13,934 |
||||||
Repayment of government loan |
(101,762 ) |
(113,885 ) |
||||||
Net cash used in financing activities |
3,660,414 |
(125,385 ) |
||||||
Effect of exchange rate changes |
51,878 |
58,871 |
||||||
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS |
1,289,737 |
(2,328,436 ) |
||||||
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD |
511,400 |
2,635,522 |
||||||
CASH AND CASH EQUIVALENTS, END OF PERIOD |
$ |
1,801,137 |
$ |
307,086 |
||||
All BIO-key shares issued and outstanding for all periods reflect BIO-key's 1-for-18 reverse stock split, which was effective December 21, 2023. |
bio-key international公司及其子公司 現金流量表簡明綜合報表 (未經審計) | ||||||||
截至9月30日的九個月 |
||||||||
2024 |
2023 |
|||||||
經營活動產生的現金流量: |
|
|
||||||
淨虧損 |
$ |
(2,916,195 ) |
$ |
(6,149,024 ) |
||||
調整以將淨虧損調節爲經營活動現金流的淨現金支出: |
|
|
||||||
折舊費 |
69,115 |
38,213 |
||||||
無形資產攤銷 |
233,269 |
217,978 |
||||||
可轉換債券公允價值變動 |
- |
(264,706 ) |
||||||
資本化合同成本的攤銷 |
128,953 |
126,057 |
||||||
應付票據的攤銷 |
64,000 |
- |
||||||
庫存儲備 |
(98,875 ) |
2,500,000 |
||||||
經營租賃權使用資產 |
(58,950 ) |
146,890 |
||||||
基於股票和認股權證的員工及顧問補償 |
162,614 |
163,584 |
||||||
基於股票的袍金 |
9,003 |
39,006 |
||||||
遞延所得稅收益 |
- |
(20,000 ) |
||||||
壞賬 |
- |
550,000 |
||||||
資產和負債的變動: |
|
|
||||||
應收賬款 |
(398,753 ) |
(434,989 ) |
||||||
來自保理商的應收款 |
50,302 |
(13,072 ) |
||||||
資本化的合同成本 |
(329,743 ) |
(107,336 ) |
||||||
按金 |
(7,975 ) |
- |
||||||
存貨 |
58,796 |
145,156 |
||||||
預付費用及其他 |
(18,695 ) |
(51,831 ) |
||||||
應付賬款 |
248,640 |
488,417 |
||||||
應計負債 |
(51,433 ) |
327,131 |
||||||
應付所得稅 |
- |
62,811 |
||||||
遞延收入 |
517,246 |
2,025,845 |
||||||
營運租賃負債 |
(60,827 ) |
(154,460 ) |
||||||
用於經營活動的淨現金 |
(2,399,508 ) |
(2,261,922 ) |
||||||
投資活動產生的現金流量: |
|
|
||||||
資本支出 |
(23,047 ) |
- |
||||||
投資活動中使用的淨現金 |
(23,047 ) |
- |
||||||
融資活動現金流量: |
|
|
||||||
應付票據的收益 |
2,000,000 |
- |
||||||
發行成本 |
(147,862 ) |
(25,434 ) |
||||||
行使warrants的收益 |
1,908,099 |
- |
||||||
員工股票認購計劃收到的現金 |
1,939 |
13,934 |
||||||
政府貸款償還 |
(101,762 ) |
(113,885 ) |
||||||
融資活動所使用的淨現金 |
3,660,414 |
(125,385 ) |
||||||
匯率變動的影響 |
51,878 |
58,871 |
||||||
現金及現金等價物淨增減額 |
1,289,737 |
(2,328,436 ) |
||||||
期初現金及現金等價物餘額 |
511,400 |
2,635,522 |
||||||
期末現金及現金等價物餘額 |
$ |
1,801,137 |
$ |
307,086 |
||||
所有bio-key發行和未流通股份在所有期間反映出bio-key的1比18的股票合併,該合併於2023年12月21日生效。 |